PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 14.3 pts more than Nifty Microcap 250 and 14.5 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biogen Pharmachem Industries reported audited standalone financial results for FY ended March 31, 2026. Total income declined significantly to Rs 135.23 lakhs from Rs 255.80 lakhs in the previous year, representing a revenue decline of approximately 47%. Despite lower revenue, the company posted a net profit after tax of Rs 85.95 lakhs compared to a loss of Rs 29.27 lakhs in FY25, showing improved profitability. The auditor issued an Unmodified Opinion (clean audit report). Cash and cash equivalents decreased from Rs 201.63 lakhs to Rs 32.16 lakhs. Operating cash flow was positive at Rs 156.83 lakhs, while financing activities included Rs 630 lakhs raised from share issuance.
Revenue has declined sharply by 47% year-on-year, which is a major concern. However, the company turned profitable from a loss last year, and the auditor gave a clean report. The sharp drop in cash reserves despite positive operating cash flow warrants monitoring.